share_log

Big Cypress Acquisition (OTCMKTS:BCYP) Vs. Orchard Therapeutics (NASDAQ:ORTX) Head-To-Head Contrast

Defense World ·  Aug 16, 2022 01:51

Big Cypress Acquisition (OTCMKTS:BCYP – Get Rating) and Orchard Therapeutics (NASDAQ:ORTX – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

Profitability

This table compares Big Cypress Acquisition and Orchard Therapeutics' net margins, return on equity and return on assets.

Get Big Cypress Acquisition alerts:
Net Margins Return on Equity Return on Assets
Big Cypress Acquisition N/A N/A N/A
Orchard Therapeutics -1,452.46% -86.92% -54.69%

Valuation & Earnings

This table compares Big Cypress Acquisition and Orchard Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Big Cypress Acquisition N/A N/A -$10,000.00 N/A N/A
Orchard Therapeutics $1.67 million 45.67 -$144.58 million ($1.33) -0.45
Big Cypress Acquisition has higher earnings, but lower revenue than Orchard Therapeutics.

Institutional & Insider Ownership

60.2% of Big Cypress Acquisition shares are owned by institutional investors. Comparatively, 56.5% of Orchard Therapeutics shares are owned by institutional investors. 3.3% of Orchard Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations for Big Cypress Acquisition and Orchard Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Big Cypress Acquisition 0 0 2 0 3.00
Orchard Therapeutics 1 2 3 0 2.33

Big Cypress Acquisition currently has a consensus price target of $17.25, indicating a potential upside of 104.38%. Orchard Therapeutics has a consensus price target of $7.75, indicating a potential upside of 1,185.03%. Given Orchard Therapeutics' higher possible upside, analysts plainly believe Orchard Therapeutics is more favorable than Big Cypress Acquisition.

Summary

Big Cypress Acquisition beats Orchard Therapeutics on 6 of the 10 factors compared between the two stocks.

About Big Cypress Acquisition

(Get Rating)

Big Cypress Acquisition Corp. does not have significant operations. The company intends to acquire assets and businesses through a merger, capital stock exchange, stock purchase, reorganization, or similar business combination. It primarily focuses in the life science sector. The company was incorporated in 2020 and is based in Miami Beach, Florida.

About Orchard Therapeutics

(Get Rating)

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

Receive News & Ratings for Big Cypress Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Big Cypress Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment